Acquired immunodeficiency syndrome

Acquired immunodeficiency syndrome
Gary van der Merwe · CC BY-SA 3.0 · source
Name	Acquired immunodeficiency syndrome
Field	Infectious disease, Immunology
Symptoms	Opportunistic infections, weight loss, fevers, night sweats, lymphadenopathy
Complications	Pneumocystis pneumonia, Kaposi sarcoma, tuberculosis, cryptococcal meningitis
Onset	Variable
Duration	Chronic
Causes	Human immunodeficiency virus
Risks	Unprotected sexual contact, injection drug use, blood transfusion, mother-to-child transmission
Diagnosis	Antibody tests, antigen tests, nucleic acid tests, CD4 count
Differential	Primary immunodeficiency, malnutrition, hematologic malignancy
Prevention	Condom use, pre-exposure prophylaxis, sterile injections, screening of blood products
Treatment	Antiretroviral therapy, opportunistic infection prophylaxis
Frequency	Millions affected globally

Acquired immunodeficiency syndrome is a chronic, life‑threatening condition resulting from progressive failure of the immune system due to infection by human immunodeficiency viruses. Recognized by opportunistic infections and certain neoplasms, it transformed global health policy, biomedical research, and civil society responses across nations and institutions. Major public figures, activist organizations, pharmaceutical companies, and international agencies shaped diagnosis, treatment, and prevention efforts over decades.

History

Early clinical descriptions emerged amid outbreaks investigated by physicians in urban centers and university hospitals, prompting epidemiologic studies by agencies such as Centers for Disease Control and Prevention and collaborations with researchers at National Institutes of Health, University of California, San Francisco, and Institut Pasteur. Controversies over initial naming, stigmatization, and laboratory discovery involved virologists at National Cancer Institute, Rockefeller University, and teams including Françoise Barré‑Sinoussi and Luc Montagnier at Institut Pasteur as well as investigators like Robert Gallo in the United States. Activist movements—led by groups such as ACT UP and advocates like Larry Kramer—pushed for accelerated drug approval by regulators including the Food and Drug Administration and reform of research funding by bodies such as the World Health Organization and UNAIDS. Legal and policy responses included antidiscrimination litigation in courts like the Supreme Court of the United States and national programs modeled after initiatives in countries such as South Africa, Brazil, and United Kingdom.

Virology and Pathogenesis

The etiologic agents were characterized by molecular studies from laboratories at Pasteur Institute of Iran and collaborations involving centers like Massachusetts General Hospital, revealing retroviral replication mediated by reverse transcriptase enzymes similar to those studied by teams at Cold Spring Harbor Laboratory and Salk Institute. Pathogenesis involves viral entry via CD4 and coreceptors investigated in structural studies at institutions including Harvard Medical School and Rockefeller University; determinants of tropism were elucidated in experiments referencing work at Johns Hopkins University and Walter Reed Army Institute of Research. Viral reservoirs and latency were mapped using techniques refined at Fred Hutchinson Cancer Research Center and Dana-Farber Cancer Institute, contributing to cure research programs at National Institutes of Health. Immune depletion mechanisms intersect with oncology findings from Memorial Sloan Kettering Cancer Center and transplant immunology insights from Mayo Clinic.

Transmission and Prevention

Modes of transmission—sexual contact, perinatal exposure, and parenteral routes—were documented in cohort studies from centers such as Karolinska Institutet, University of Cape Town, and Makerere University. Prevention strategies include behavioral interventions promoted by public health agencies like Centers for Disease Control and Prevention and World Health Organization, biomedical interventions developed by pharmaceutical firms such as Gilead Sciences and ViiV Healthcare, and community programs led by NGOs including Médecins Sans Frontières and Bill & Melinda Gates Foundation-funded initiatives. Biomedical prevention milestones include pre-exposure prophylaxis trials coordinated by research networks at University of Washington and implementation science from London School of Hygiene & Tropical Medicine. Blood safety advances trace to regulatory reforms in countries like France, Germany, and Japan.

Clinical Presentation and Diagnosis

Clinical syndromes and opportunistic diseases were cataloged in textbooks from publishers collaborating with clinicians at Johns Hopkins Hospital, Massachusetts General Hospital, and specialty centers such as St. Mary's Hospital, London. Presentations range from acute viral syndrome described in case series from urban clinics in New York City and San Francisco to chronic wasting and opportunistic infections studied in referrals to Groote Schuur Hospital and Chris Hani Baragwanath Hospital. Diagnostic assays—enzyme immunoassays, p24 antigen tests, and nucleic acid amplification—were commercialized by companies like Abbott Laboratories and Roche and validated in trials at research centers including Imperial College London and McGill University. Laboratory monitoring of disease progression uses CD4 counts and viral load assays standardized by bodies such as World Health Organization and professional societies like the Infectious Diseases Society of America.

Treatment and Management

Combination antiretroviral therapy regimens were developed through randomized trials coordinated by networks such as INSIGHT and funded by agencies including National Institutes of Health and philanthropic partners like Wellcome Trust. Drug classes—nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors—were discovered by pharmaceutical firms including Merck & Co., Bristol Myers Squibb, and GlaxoSmithKline and incorporated into treatment guidelines from organizations such as World Health Organization and International AIDS Society. Clinical management integrates opportunistic infection prophylaxis protocols from hospitals like King's College Hospital and primary care models piloted by community clinics supported by PEPFAR. Implementation challenges prompted health systems research at Columbia University and University of Nairobi to optimize retention in care and adherence interventions championed by advocacy groups including Treatment Action Group.

Epidemiology and Public Health Impact

Global surveillance conducted by UNAIDS and analytical reports from World Health Organization track incidence and prevalence patterns influenced by social determinants studied by scholars at University of Oxford, Harvard University, and London School of Economics. Epidemic trajectories in regions such as southern Africa, eastern Europe, and southeast Asia prompted national responses in states including South Africa, Russia, and Thailand and multinational funding mechanisms like Global Fund to Fight AIDS, Tuberculosis and Malaria and programs by United States Agency for International Development. The pandemic influenced research funding priorities at foundations such as Gates Foundation and reshaped health diplomacy through summits convened by United Nations and leaders from countries including Brazil, India, and China. Public health lessons informed responses to later outbreaks investigated by institutions like Centers for Disease Control and Prevention and European Centre for Disease Prevention and Control.

Category:Infectious diseases